Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
Omar Abdel-RahmanPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
DM does not seem to affect overall or progression-free survival of mCRC patients treated with first-line FOLFOX chemotherapy. Moreover, DM does not influence the incidence or severity of oxaliplatin-induced paresthesia in those patients while it might lead to a shorter time to develop oxaliplatin-induced paresthesia compared to non-diabetic patients.
Keyphrases
- metastatic colorectal cancer
- phase iii
- free survival
- high glucose
- end stage renal disease
- diabetic rats
- type diabetes
- open label
- clinical trial
- glycemic control
- newly diagnosed
- locally advanced
- chronic kidney disease
- drug induced
- risk factors
- endothelial cells
- prognostic factors
- squamous cell carcinoma
- randomized controlled trial
- double blind
- patient reported outcomes
- metabolic syndrome
- insulin resistance
- patient reported